X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Transformative acquisition deepens pipeline with In-process phase 2/3 clinical study of proprietary oral formulation of Niclosamide for the treatment of covid-19 development timeline supports multiple value drivers over next 12-18 months.
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: ANA-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NeuroBo Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 06, 2021
Details:
The trial is the first in the U.S. to test the potential of niclosamide for COVID-19. Company begun Phase 2/3 clinical trial to evaluate the safety and efficacy of oral niclosamide (ANA001) formulation for the treatment of patients with moderate COVID-19 disease.
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: ANA001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19.
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: ANA001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quotient Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 11, 2020
Details:
ANA will evaluate both the safety of niclosamide as well as its ability to show a clinical improvement in hospitalized patients with COVID-19. This study will focus on patients with less severe symptoms who are not on ventilators.
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: ANA001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
